文献速递妇科

贝伐珠单抗联合瑞卡帕尼治疗复发性宫颈癌或子宫内膜癌的II期试验

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
PubMed 文献 · Gynecol Oncol · 2022-04-28

该II期试验纳入33例一线治疗后进展的复发性宫颈癌或子宫内膜癌患者,接受贝伐珠单抗联合瑞卡帕尼治疗。子宫内膜癌缓解率17%,宫颈癌14%;中位无进展生存期3.8个月,中位总生存期10.1个月;ARID1A突变患者缓解率33%、6个月无进展生存率67%。结论认为联合方案未在所有患者中显著提高抗肿瘤活性,但ARID1A突变亚组可能获益,需进一步研究确认。

要点

  • 子宫内膜癌缓解率17%,宫颈癌缓解率14%。
  • 中位无进展生存期3.8个月,中位总生存期10.1个月。
  • ARID1A突变患者缓解率33%、6个月无进展生存率67%,高于全体研究人群。

核心结论

  • 贝伐珠单抗联合瑞卡帕尼未在所有复发性宫颈癌或子宫内膜癌患者中显示显著增加的抗肿瘤活性。
  • ARID1A突变患者有更高的缓解率和6个月无进展生存率,提示该亚组可能从联合治疗中获益。
  • 需进一步研究确认该观察结果,未观察到新的安全性信号。

研究设计与样本

  • II期试验,纳入33例一线治疗后进展的转移性或复发性宫颈癌或子宫内膜癌患者。
  • 瑞卡帕尼600 mg每日两次,每21天周期给药;贝伐珠单抗15 mg/kg,每21天周期第1天给药。
  • 主要终点为客观缓解率或6个月无进展生存确定的疗效,28例可评估。

主要发现

  • 子宫内膜癌患者缓解率17%,宫颈癌患者缓解率14%。
  • 中位无进展生存期3.8个月(95%CI 2.5至5.7个月),中位总生存期10.1个月(95%CI 7.0至15.1个月)。
  • ARID1A突变患者缓解率33%、6个月无进展生存率67%,高于全体研究人群。
  • 观察到的毒性与此前贝伐珠单抗和瑞卡帕尼研究相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究确认ARID1A突变亚组获益的观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to examine the tolerability and efficacy of combination bevacizumab rucaparib therapy in patients with recurrent cervical or endometrial cancer. PATIENTS & METHODS: Thirty-three patients with recurrent cervical or endometrial cancer were enrolled. Patients were required to have tumor progression after first line treatment for metastatic, or recurrent disease. Rucaparib was given at 600 mg BID twice daily for each 21-day cycle. Bevacizumab was given at 15 mg/kg on day 1 of each 21-day cycle. The primary endpoint was efficacy as determined by objective response rate or 6-month progression free survival. RESULTS: Of the 33 patients enrolled, 28 were evaluable. Patients with endometrial cancer had a response rate of 17% while patients with cervical cancer had a response rate of 14%. Median progression free survival was 3.8 months (95% C·I 2.5 to 5.7 months), and median overall survival was 10.1 months (95% C·I 7.0 to 15.1 months). Patients with ARID1A mutations displayed a better response rate (33%) and 6-month progression free survival (PFS6) rate (67%) than the entire study population. Observed toxicity was similar to that of previous studies with bevacizumab and rucaparib. CONCLUSIONS: The combination of bevacizumab with rucaparib did not show significantly increased anti-tumor activity in all patients with recurrent cervical or endometrial cancer. However, patients with ARID1A mutations had a higher response rate and PFS6 suggesting this subgroup may benefit from the combination of bevacizumab and rucaparib. Further study is needed to confirm this observation. No new safety signals were seen.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Jackson CG, Moore KN, Cantrell L, et al. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022. PMID: 35491267. doi:10.1016/j.ygyno.2022.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。